Becton Dickinson 配当と自社株買い
配当金 基準チェック /56
Becton Dickinsonは配当を支払う会社で、現在の利回りは2.81%ですが、利益によって十分にカバーされています。次の支払い日は 30th June, 2026で、権利落ち日は9th June, 2026 。
主要情報
2.8%
配当利回り
1.2%
バイバック利回り
| 総株主利回り | 4.0% |
| 将来の配当利回り | 2.6% |
| 配当成長 | 4.7% |
| 次回配当支払日 | 30 Jun 26 |
| 配当落ち日 | 09 Jun 26 |
| 一株当たり配当金 | n/a |
| 配当性向 | 68% |
最近の配当と自社株買いの更新
Recent updates
BDX: Cautious Reset In FY26 Expectations And Execution Risks Will Shape Outlook
Becton Dickinson's analyst price target has been reset from $183 to $157 as analysts factor in more cautious revenue growth, slightly softer profit margins, a higher discount rate, and a lower assumed future P/E multiple. Analyst Commentary Recent Street research around Becton Dickinson reflects a more cautious tone, with a series of price target resets and neutral stances shaping expectations for risk and reward.Becton, Dickinson: Value Or Overvalued Even Now?
Apr 20
BDX: 2026 MedTech Setup And Buybacks Will Support Upside Potential
Analyst price targets for Becton Dickinson have edged lower, with the fair value estimate moving from about $196.08 to $192.31 as analysts factor in slightly higher discount rates, modestly softer revenue growth and profit margins, and a somewhat higher future P/E multiple. Analyst Commentary Recent Street research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess execution risks and valuation assumptions.BDX: 2026 MedTech Setup And Tuck In M&A Will Support Upside
Analysts have trimmed their average price target for Becton Dickinson by about $1, reflecting slightly lower fair value and P/E assumptions, along with modestly higher profit margin expectations. Analyst Commentary Recent Street research on Becton Dickinson has featured several price target changes and rating actions that point to a mix of optimism about execution and caution around valuation and growth assumptions.BDX: 2026 MedTech Setup And Tuck In M&A Will Drive Upside
Narrative Update The latest analyst work on Becton Dickinson points to a mixed shift in price targets, with some firms raising their views by $12.30 to $15.00 while others trimmed estimates by $1.00 to $38.00, as analysts reassessed near term pressures, longer term MedTech prospects into 2026, and valuation assumptions including discount rate and future P/E inputs. Analyst Commentary Recent Street research on Becton Dickinson points to a split view, with some analysts lifting targets and others trimming them as they rework models for 2025 pressures and the setup into 2026.BDX: 2026 MedTech Setup And Buybacks Will Shape Upside Potential
The analyst price target for Becton Dickinson has been adjusted to approximately $197 from about $195, as analysts factor in recently updated views on large cap MedTech setups, leading to slightly higher fair value and P/E assumptions. Analyst Commentary Recent research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess large cap MedTech names and Becton Dickinson's role within that group.BDX: 2026 Reset With Mixed Research And Product Pipeline Will Shape Returns
Analysts have trimmed their average price target on Becton Dickinson by about $9 to reflect more cautious assumptions on revenue growth and margins. This is partly offset by a willingness to apply a higher future P/E multiple as recent research updates reset expectations across the sector.
BDX: FY26 Guidance Reset Will Support More Constructive 2026 MedTech Setup
Narrative update The analyst price target for Becton Dickinson has been revised from about US$322 to about US$253. Analysts cite updated assumptions for growth, margins and future P/E, and they also reflect mixed recent Street research that includes both target raises and cuts following FY26 guidance and Q4 results.Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05
Jan 31
BDX: FY26 Reset And Alaris China And Vaccine Headwinds Will Pressure Outlook
Analysts have modestly adjusted their price expectations for Becton Dickinson, with recent Street targets ranging from a reduction to $202 to an increase to $215. They are balancing near term headwinds in areas like Alaris, China, and vaccines against what some see as a more constructive setup heading into 2026 for large cap MedTech.BDX: 2026 Reset And Headwinds Will Shape Fairly Balanced Return Potential
Analysts have modestly adjusted their fair value estimate for Becton Dickinson to about $205 per share, reflecting updated views on slower profit margin assumptions, a somewhat higher future P/E, and recent price target resets around $202 to $210 following Q4 results and FY26 guidance. Analyst Commentary Recent Street research has focused on how Becton Dickinson's latest Q4 results and FY26 outlook feed into valuation, execution risk, and growth expectations.BDX: FY26 Reset And Business Separation Will Shape Balanced Risk Reward Outlook
We raise our fair value estimate for Becton Dickinson to $183 from $172 per share, reflecting analysts' view that a conservative FY26 reset, modestly higher long term profitability, and a slightly richer future earnings multiple more than offset near term revenue growth headwinds and higher risk premia embedded in the discount rate. Analyst Commentary Bearish analysts are converging around a more cautious outlook for Becton Dickinson, trimming price targets and highlighting execution risks that could cap near term upside.BDX: 2026 Separation And Reset Outlook Will Shape Returns Amid Headwinds
Analysts have modestly lowered their price target on Becton Dickinson to about $203 per share from roughly $201 previously. This reflects slightly higher long term revenue growth assumptions, offset by a marginally lower profit margin outlook and cautious views on FY26 guidance amid Alaris, China, and vaccine related headwinds.Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05
Nov 24BDX: Modest Guidance and 2026 Separation Will Shape Future Performance Amid Headwinds
Becton Dickinson's analyst price target was reduced from approximately $206.58 to $201.49. Analysts attribute this change to cautious forward guidance, modest revenue expectations, and ongoing external headwinds highlighted in recent reports.Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings
Nov 16Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05
Nov 09BDX Will Unlock New Growth Following Planned 2026 Business Separation
Becton Dickinson Analyst Price Target Narrative Update The analyst fair value estimate for Becton Dickinson was reduced slightly from $208 to approximately $206.58, with analysts citing a more conservative earnings outlook and limited growth expectations in the near term. Analyst Commentary Analyst perspectives on Becton Dickinson reflect a balanced view of the company’s near-term challenges and long-term opportunities.Becton, Dickinson and Company: It's Wait And See For Me
Apr 27Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline
Mar 30配当金の支払いについて
決済の安定と成長
配当データの取得
安定した配当: BDXの1株当たり配当金は過去10年間安定しています。
増加する配当: BDXの配当金は過去10年間にわたって増加しています。
配当利回り対市場
| Becton Dickinson 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (BDX) | 2.8% |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.2% |
| 業界平均 (Medical Equipment) | 2.2% |
| アナリスト予想 (BDX) (最長3年) | 2.6% |
注目すべき配当: BDXの配当金 ( 2.81% ) はUS市場の配当金支払者の下位 25% ( 1.4% ) よりも高くなっています。
高配当: BDXの配当金 ( 2.81% ) はUS市場の配当金支払者の上位 25% ( 4.22% ) と比較すると低いです。
株主への利益配当
収益カバレッジ: BDXの配当金は、合理的な 配当性向 ( 68% ) により、利益によって賄われています。
株主配当金
キャッシュフローカバレッジ: BDXの 現金配当性向 ( 45.5% ) は比較的低く、配当金の支払いはキャッシュフローによって十分にカバーされています。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/03 12:47 |
| 終値 | 2026/05/01 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/09/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Becton, Dickinson and Company 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。35
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Adam Feinstein | Barclays |
| Matthew Miksic | Barclays |